Analysts Expect Exelixis, Inc. (EXEL) to Announce $0.25 Earnings Per Share

Equities analysts expect Exelixis, Inc. (NASDAQ:EXEL) to report earnings per share of $0.25 for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Exelixis’ earnings, with estimates ranging from $0.16 to $0.33. Exelixis posted earnings per share of $0.12 during the same quarter last year, which would indicate a positive year-over-year growth rate of 108.3%. The company is scheduled to report its next quarterly earnings results on Monday, February 25th.

On average, analysts expect that Exelixis will report full-year earnings of $1.30 per share for the current fiscal year, with EPS estimates ranging from $1.22 to $1.37. For the next fiscal year, analysts anticipate that the firm will post earnings of $1.25 per share, with EPS estimates ranging from $0.91 to $1.55. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Exelixis.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.19 by $0.22. The company had revenue of $225.40 million for the quarter, compared to the consensus estimate of $174.14 million. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. Exelixis’s quarterly revenue was up 47.8% on a year-over-year basis. During the same period last year, the business posted $0.26 EPS.

Several research firms have commented on EXEL. Stifel Nicolaus reduced their price objective on Exelixis from $29.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, August 1st. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $25.00 target price on the stock in a research report on Tuesday, July 31st. BidaskClub cut Exelixis from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 11th. Morgan Stanley initiated coverage on Exelixis in a research report on Monday, September 10th. They set an “underweight” rating and a $19.00 target price on the stock. Finally, Piper Jaffray Companies dropped their target price on Exelixis from $29.00 to $26.00 and set an “overweight” rating on the stock in a research report on Monday, November 5th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $29.44.

EXEL opened at $16.67 on Wednesday. The firm has a market cap of $5.18 billion, a price-to-earnings ratio of 32.69, a PEG ratio of 1.03 and a beta of 2.29. Exelixis has a 52 week low of $13.42 and a 52 week high of $32.20. The company has a current ratio of 8.66, a quick ratio of 8.54 and a debt-to-equity ratio of 0.01.

In other news, insider Michael Morrissey sold 90,000 shares of the firm’s stock in a transaction on Monday, August 20th. The stock was sold at an average price of $17.82, for a total value of $1,603,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Vincent T. Marchesi sold 40,000 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $19.50, for a total value of $780,000.00. The disclosure for this sale can be found here. Insiders sold a total of 321,500 shares of company stock valued at $5,646,160 in the last three months. Insiders own 4.80% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. raised its stake in Exelixis by 16.7% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 20,599 shares of the biotechnology company’s stock worth $443,000 after acquiring an additional 2,948 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in Exelixis by 17.1% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 23,496 shares of the biotechnology company’s stock worth $416,000 after acquiring an additional 3,428 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in Exelixis by 31.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 17,220 shares of the biotechnology company’s stock worth $371,000 after acquiring an additional 4,095 shares during the last quarter. Meeder Asset Management Inc. raised its stake in Exelixis by 21.2% in the 3rd quarter. Meeder Asset Management Inc. now owns 23,504 shares of the biotechnology company’s stock worth $416,000 after acquiring an additional 4,117 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in Exelixis by 5.1% in the 1st quarter. Principal Financial Group Inc. now owns 91,006 shares of the biotechnology company’s stock worth $2,016,000 after acquiring an additional 4,445 shares during the last quarter. 81.84% of the stock is owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: What is a Swap?

Get a free copy of the Zacks research report on Exelixis (EXEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply